Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 362 miles
Innovative Clinical Research Institute
Whittier,CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03858972

Tesetaxel and Capecitabine for HER2 negative, HR positive Advanced Breast Cancer

Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane (CONTESSA 2) Scientific Title

Purpose
To study the effects (good and bad) of tesetaxel when used with a reduced dose of capecitabine (Xeloda®).
Who is this for?
Women and men with locally advanced (some stage III) or metastatic (stage IV) breast cancer that is ER positive and HER2 negative and have not been previously treated with a taxane.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tesetaxel, by mouth, once every 3 weeks</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, twice a day for 14 out of every 21 days</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tesetaxel is a new type of taxane chemotherapy drug that can be taken by mouth. </li> <li class="seamTextUnorderedListItem">The taxanes that are currently approved are all given intraveneously (IV). </li> <li class="seamTextUnorderedListItem">Xeloda® is an oral chemotherapy drug approved to treat advanced breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03858972' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.odonate.com/tesetaxel' target='_blank'>Sponsor site: Tesetaxel</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-7777/capecitabine-oral/details' target='_blank'>WebMD: Capecitabine</a> </li></ul>
See more